Notebookcheck Logo

MySugarWatch needle-free continuous glucose monitor for type 2 diabetes on the cards as award-winning Nemaura posts encouraging financials

MySugarWatch has licensed the glucose monitor form of the BEAT sensor from Nemaura. (Image source: MySugarWatch - edited)
MySugarWatch has licensed the glucose monitor form of the BEAT sensor from Nemaura. (Image source: MySugarWatch - edited)
Nemaura, the British company behind the BEAT technology platform for biomarker monitoring, has announced promising financial results. In addition, the firm has also recently won two innovation awards for its work with non-invasive biosensors. The results bode well for MySugarWatch, which aims to give type 2 diabetics an affordable needle-free continuous glucose monitor.

Double news about Nemaura has indirectly increased the prospects of the needle-free MySugarWatch non-invasive continuous glucose monitor (CGM) becoming available in 2022. While it’s always worthwhile to remain cautious about any news related to a pain-free or fingerstick-free method for taking accurate glucose level measurements, the fact that so many companies are investigating a solution lends weight to an eventual positive outcome. MySugarWatch is a licensee of the BEAT sensor, also known as SugarBEAT, from Nemaura Medical.

Not only has Nemaura won an Innovation in Med Tech and Life Sciences Award and Innovator of the Year 2022 Award with the LeicestershireLive Innovation Awards in the UK recently, but it also posted a promising quarterly financial report revealing two indicators that show work on a needle-free non-invasive CGM was likely forging ahead. The company had US$183,628 due thanks to shipments of its BEAT sensor to MySugarWatch and, crucially, it had US$23 million in cash reserves. This latter figure is important as it shows Nemaura has enough capital to continue with costly but vital research and development.

The SugarBEAT non-invasive CGM has been around for a while, even getting its CE Mark (sales approval in the European Union) in 2019. However, it was clear that more testing and refining was required for the device, which is simply attached to the top of the arm with a disposable adhesive patch and measures glucose levels by attracting the relevant molecules from the interstitial fluid (see slide below). A transmitter in the device constantly sends data to an app via Bluetooth, allowing the wearer to keep an eye on their glycemic state.

A corporate presentation from 2019 revealed that Nemaura wanted to make its SugarBEAT sensor affordable; at the time a figure of US$30 was suggested for 8 patches a month (non-insulin users) or US$55 for 16 patches (for insulin users) with both amounts based on an annual subscription and with the transmitter and recharger included. It remains to be seen what MySugarWatch’s plans are in regard to cost, as the company’s website offers few details at the moment, with its device apparently “available soon”.

Buy Fixic Freestyle Adhesive patches on Amazon

The BEAT sensor is not much bigger than a UK £1 coin. (Image source: Nemaura)
BEAT sensor
How it works
How it works
Cost. (Image source: Nemaura/SlideShare)
Cost
Read all 4 comments / answer
static version load dynamic
Loading Comments
Comment on this article
Please share our article, every link counts!
> Expert Reviews and News on Laptops, Smartphones and Tech Innovations > News > News Archive > Newsarchive 2022 02 > MySugarWatch needle-free continuous glucose monitor for type 2 diabetes on the cards as award-winning Nemaura posts encouraging financials
Daniel R Deakin, 2022-03- 1 (Update: 2022-03- 1)